Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

This treatment has been approved for sale to the public.
Sponsor:
Information provided by (Responsible Party):
Genentech, Inc.
ClinicalTrials.gov Identifier:
NCT01160250
First received: July 8, 2010
Last updated: October 28, 2014
Last verified: October 2014

July 8, 2010
October 28, 2014
July 2010
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT01160250 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
A Single-Arm, Open-Label, Expanded Access Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

This is an open-label, non-comparative, multicenter, expanded access study of Vismodegib (GDC-0449) in patients with locally advanced basal cell carcinoma (BCC) or metastatic BCC (mBCC) who are otherwise without satisfactory treatment options.

Not Provided
Expanded Access
Phase 2
Not Provided
Basal Cell Carcinoma
Drug: Vismodegib (GDC-0449)
Oral repeating dose
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Approved for marketing
Not Provided
April 2012
Not Provided

Inclusion Criteria:

  • For patients with mBCC, histologic confirmation of distant BCC metastasis
  • For patients with locally advanced BCC, at least one histologically confirmed lesion 10 mm or more in diameter and written confirmation from a surgical specialist that the tumor is considered inoperable or that surgery is contraindicated
  • For patients with locally advanced BCC, radiotherapy must have been previously administered for locally advanced BCC, unless radiotherapy is contraindicated or inappropriate. For patients whose locally advanced BCC has been irradiated, disease must have progressed after radiation.
  • Patients with Gorlin syndrome may enroll in this study but must meet the criteria for locally advanced or metastatic disease listed above
  • Patients with measurable and/or non-measurable disease (as defined by RECIST) are allowed
  • Adequate organ function
  • For women of childbearing potential, agreement to the use of two acceptable methods of contraception, including one barrier method, during the study and for 12 months after discontinuation of Vismodegib (GDC-0449)
  • For men with female partners of childbearing potential, agreement to use a latex condom, and to advise their female partner to use an additional method of contraception during the study and for 3 months after discontinuation of Vismodegib (GDC-0449)

Exclusion Criteria:

  • Pregnancy or lactation
  • Life expectancy < 12 weeks
  • Concurrent non-protocol-specified anti-tumor therapy
  • Completion of most recent anti-tumor therapy at least 21 days prior to initiation of treatment
  • Uncontrolled medical illnesses such as infection requiring treatment with intravenous antibiotics
  • History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or that might affect interpretation of the results of the study or renders the patient at high risk from treatment complications
  • Unwillingness to practice effective birth control
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01160250
SHH4811g
Not Provided
Genentech, Inc.
Genentech, Inc.
Not Provided
Study Director: Diana M. Chen, MD, FAAD Genentech, Inc.
Genentech, Inc.
October 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP